142 related articles for article (PubMed ID: 37561041)
1. Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection.
Park CH; Park JH; Jung YS
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00632. PubMed ID: 37561041
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Sohn CI; Park CH
Gut Liver; 2023 Sep; 17(5):711-721. PubMed ID: 36510776
[TBL] [Abstract][Full Text] [Related]
3. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
Jung YS; Kim S; Kim HY; Noh SJ; Park JH; Park CH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1911-1918. PubMed ID: 35816283
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for
Park CH; Song MJ; Jung BW; Park JH; Jung YS
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36422094
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with
Lee YD; Kim SE; Park SJ; Park MI; Moon W; Kim JH; Jung K; Song J
Korean J Gastroenterol; 2020 Sep; 76(3):142-149. PubMed ID: 32969362
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
Kim JS; Ko W; Chung JW; Kim TH
Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
[TBL] [Abstract][Full Text] [Related]
8. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
9. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of
Choi YJ; Lee YC; Kim JM; Kim JI; Moon JS; Lim YJ; Baik GH; Son BK; Lee HL; Kim KO; Kim N; Ko KH; Jung HK; Shim KN; Chun HJ; Kim BW; Lee H; Kim JH; Chung H; Kim SG; Jang JY
Gut Liver; 2022 Jul; 16(4):535-546. PubMed ID: 35791797
[TBL] [Abstract][Full Text] [Related]
10. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
11. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
[TBL] [Abstract][Full Text] [Related]
12. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
14. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
16. Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication.
Kwon YH; Jeon SW; Nam SY; Lee DW; Park JH; Bae HJ
Korean J Intern Med; 2023 Jul; 38(4):493-503. PubMed ID: 37369525
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Hsu PI; Lai KH; Lin CK; Chen WC; Yu HC; Cheng JS; Tsay FW; Wu CJ; Lo CC; Tseng HH; Yamaoka Y; Chen JL; Lo GH
Am J Gastroenterol; 2005 Nov; 100(11):2387-92. PubMed ID: 16279889
[TBL] [Abstract][Full Text] [Related]
18. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
19. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
20. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
